LON:SAG - Science Group PLC
Executive Summary
Science Group PLC (LON:SAG) is an Industrials company within Consulting Services that provides science-led research, technology and product-development services to organisations across medical, consumer, food and beverage, and industrial markets. Its market position is based on specialist technical capabilities and established client relationships rather than scale, with the group operating through Science Group and Oakdene Hollins.
The investment case requires earnings to stabilise following the recent contraction, continued client retention and further evidence that share repurchases can translate into per-share value creation; the key near-term catalyst is the next full-year trading update, expected in March 2027 based on the company's established annual reporting cycle, although the precise date is not confirmed. The primary risk is disproportionate earnings damage from the loss of a major client amid disclosed client-concentration and economic-sensitivity risks.
OPPORTUNISTIC BUY. Conviction Score: 64/100. A sustained revenue recovery, stronger earnings and a named contract win would strengthen the case, while a material client loss, further significant earnings contraction or an adverse refinancing environment would invalidate the thesis.
Thesis break: The thesis would be invalidated by the loss of a major client, a further material decline in revenue or earnings, or a dilutive capital raise that signals that the balance sheet cannot support the current buyback and recovery assumptions.
Business Model
Science Group PLC earns revenue primarily from project-based research, development and consulting work. Science Group provides technology and product-development services that include concept development, prototyping, regulatory support and commercialisation assistance, while Oakdene Hollins provides sustainability consultancy focused on food, drink and agri-business clients. Engagements use a mix of fixed-fee and time-and-materials structures, making revenue dependent on contract scope, project completion and the ability to maintain utilisation.
The customer base comprises organisations in medical, consumer, food and beverage, and industrial end markets. The prior research indicates that relationships can be long-lived and that the top ten clients account for a meaningful share of group revenue, although no current revenue-mix percentages were supplied. The model is people-intensive and historically generated mid-teens EBIT margins on revenue of approximately GBP 95 million in FY2024, but those historical figures should not be treated as a current forecast following the earnings contraction identified in the latest research.
The principal competitive advantage is specialised scientific and engineering expertise combined with client intimacy and a reputation for supporting technically demanding projects. This is a moderate rather than wide moat: switching costs can rise during multi-stage development programmes, but clients retain negotiating power, especially where a large contract represents a significant proportion of group revenue. The balance sheet is reinforced by treasury-share purchases, although buybacks cannot substitute for organic revenue growth or resolve client-concentration risk.
Financial Snapshot
Recent Catalysts
[2026-05-14] - Science Group PLC announced that it had purchased 5,000 ordinary shares on 14 May 2026 at an average price of 594p per share, representing 0.01% of voting rights before the purchase; the shares were held in treasury. Source: Science Group PLC regulatory announcement.
[2026-05-13] - Science Group PLC announced that it had purchased 10,000 ordinary shares on 13 May 2026 at an average price of 595p per share, representing 0.02% of voting rights before the purchase; the shares were held in treasury. Source: Science Group PLC regulatory announcement.
[2026-05-12] - Science Group PLC announced that it had purchased 20,500 ordinary shares on 12 May 2026 at an average price of 596p per share, representing 0.05% of voting rights before the purchase; the shares were held in treasury. Source: Science Group PLC regulatory announcement.
[2026-05-11] - Science Group PLC announced that it had purchased 21,000 ordinary shares on 11 May 2026 at an average price of 590p per share; the transaction continued the buyback programme, with the purchased shares designated for treasury. Source: Science Group PLC regulatory announcement.
[2026-03-17] - Science Group PLC issued its latest reported quarterly earnings, with the available research recording earnings per share of 40.20 GBX; the supplied data does not provide sufficient verified detail to attribute a specific operational catalyst to the release. Source: Markets Daily earnings report.
[2026-04-13] - Science Group PLC reached a new 52-week high according to the supplied market report, which identified 17 March 2026 as the date of its latest earnings release; the event confirms positive recent market sentiment but does not establish a new fundamental contract catalyst. Source: Markets Daily.
Thesis Evaluation
Bull Case (32% weight)
Revenue stabilises and then returns to growth, earnings recover from the recent contraction and management secures at least one named contract that materially offsets client attrition. Continued treasury-share purchases support per-share metrics, and a rerating towards the supplied 13.13x forward earnings multiple alongside earnings recovery supports a 12-month target of 650p.
Base Case (49% weight)
Revenue remains broadly stable but earnings recover only gradually, while the buyback provides modest per-share support without replacing organic growth. The 12-month target of 585p represents limited upside from the current 567p price and assumes no major contract loss or acquisition.
Bear Case (19% weight)
The loss of a top client causes a disproportionate decline in revenue and profit, demonstrating that concentration risk outweighs buyback support. Further earnings contraction and multiple compression support a 12-month target of 450p.
Key Risks
- Client concentration: The disclosed dependence of revenue and earnings on major clients means that losing one top account could reduce earnings disproportionately. Estimated probability: 25%. Impact: severe.
- Earnings contraction: A further deterioration from the reported earnings decline would undermine the central assumption that profit has reached a trough. Estimated probability: 30%. Impact: severe.
- Economic sensitivity: Project demand and client spending may weaken in a slower economic environment, reducing new work and utilisation across the consultancy. Estimated probability: 35%. Impact: moderate.
- Lack of hard commercial catalysts: No named supply agreement, material contract win or acquisition has been evidenced to provide a clear organic growth trigger. Estimated probability: 45%. Impact: moderate.
- Buyback execution risk: Repurchases near the upper end of the share-price range may destroy value if earnings remain weak or if the buyback is insufficient to offset dilution and business contraction. Estimated probability: 30%. Impact: low.
- Liquidity and market risk: Science Group PLC is a small-capitalisation AIM-listed company whose share price may react disproportionately to client news, trading volumes and broader risk appetite. Estimated probability: 35%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: investors who accept small-capitalisation equities, can tolerate earnings and client-concentration volatility, and have a minimum holding period of 12 months for earnings stabilisation and buyback accretion to become visible. The appropriate risk tolerance is moderate-to-high, with position sizing that reflects the absence of a confirmed contract catalyst and the potential for material drawdowns following adverse client news.
Avoid if: investors require recurring dividends, substantial near-term revenue visibility, defensive earnings characteristics or a minimum three-year holding horizon. The stock should also be avoided by investors unwilling to accept that the loss of one major client could cause a disproportionate earnings decline.
Recommendation
OPPORTUNISTIC BUY - 64/100. Science Group PLC offers a measured recovery proposition supported by specialist services, treasury-share purchases and potential earnings normalisation, but the tier reflects material uncertainty surrounding revenue contraction, client concentration and the absence of a named commercial catalyst. An upgrade would require a sustained recovery in revenue and earnings, evidence that major-client relationships remain secure, and at least one material contract win. The call would degrade if earnings continue to contract, a significant client is lost, or cash generation weakens enough to undermine the buyback without supporting a credible organic recovery. At the current price of 567.00p the shares trade above our buy ceiling of 495.00p: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is 580.15p, 2% above the current price of 567.00p - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below 495.00p - below this level the upside to the base-case target (585.00p) is at least 2x the downside to the bear case (450.00p), the minimum risk/reward we require before committing new capital.
between 495.00p and 585.00p - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above 585.00p - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 32%.
if the thesis would be invalidated by the loss of a major client, a further material decline in revenue or earnings, or a dilutive capital raise that signals that the balance sheet cannot support the current buyback and recovery assumptions, regardless of price - the bear target of 450.00p is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 64/100. Trend versus prior report: Initiation.
| Report date | Conviction |
|---|---|
| 2026-10-28 | 64 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Company regulatory announcements, company earnings information, public financial news coverage, web research and analyst commentary were used to assess recent trading activity, earnings direction and the absence of a confirmed named commercial catalyst.
Primary source types: Regulatory announcements, company investor relations materials, company annual and interim reports, earnings releases and earnings-call transcripts, supplemented by third-party financial news and analyst commentary.
Key sources
- Science Group 2026 Company Profile: Stock Performance & Earnings | PitchBook
- Science Group (AIM:SAG) Stock Price & Overview
- Transaction in own shares
- Science Group RNS Announcements | SAG RNS Announcements | Investegate
- Science Group (SAG) Share Price, Stock Value, News & Analysis
- Science Group PLC (SAG:LSE) Share price, analysis, charts, news, dividends, EPS forecasts, annual reports and RNS - Investors Chronicle
- News | Science Group
- Investor information | Science Group
- SAG-AFTRA union secures AI protections for artists in deal with major record labels
- Science Group Plc Announces Climb In Full Year Bottom Line
Analysis generated 2026-10-28. Market data as of 2026-11-12.